🔥🔥#ESMO26 胸部肿瘤领域重点摘要：
#DeLLphi305：
III期（n=563）：Tarlatamab + Durvalumab vs Durvalumab，用于ES-SCLC患者化疗-IO后的1L维持治疗
如果我们能够在社区中让更多患者用上该药，肯定会改变临床实践，将tarlatamab推进至1L维持治疗
▶️中位OS：21.1 vs 12.7个月（HR 0.42）🔥
▶️12个月OS：79.4% vs 53.3%
▶️中位PFS：7.4 vs 1.9个月（HR 0.34）
▶️ORR：26.4% vs 4.1%
⚠️ ≥3级AEs：46.8% vs 40.6%；CRS 49.6%（大多为低级别）。
#lcsm
@SclcSMASHERS
2 浏览 · 0 赞 · 0 转发 · 1 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Dr. Estela Rodriguez@Latinamd
@SclcSMASHERS @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @glopesmd @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @NaglaAKarimMD @Annechiangmd @IASLC @larvol @oncbrothers @chinmay @Jani_Chinmay @colazagasti @myesmo
来源：Dr. Estela Rodriguez · x.com